1
|
Stocker KJ, Tiemann A, Brunk KM, Agegnehu B, Buhlinger K, Amerine L, Roberts MC, McLaughlin JE, Clark SM, Rose R, Mekonnen B, Bhakta N, Fentie AM, Alexander TB, Ozawa S, Chargualaf M, Muluneh B. Processes and perceptions of chemotherapy supply chain in Ethiopia: A mixed-method study. J Oncol Pharm Pract 2023; 29:1555-1564. [PMID: 36303425 DOI: 10.1177/10781552221134254] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2023]
Abstract
BACKGROUND The impact and downstream effects of the chemotherapy supply chain in Ethiopia are not well understood. The purpose of this study was to identify perceived gaps in supply chain and characterize their impact on patient care. METHODS A concurrent mixed-method study was conducted at a large academic cancer center in Ethiopia. In-depth interviews (IDIs) and surveys were completed in collaboration with external stakeholders with knowledge about chemotherapy supply chain in Ethiopia. Thematic coding was used for qualitative analysis of IDI and descriptive statistics were used to summarize quantitative survey data. RESULTS Six stakeholders participated in the IDIs and seven completed surveys. IDIs revealed that most chemotherapeutic agents are purchased by the Ethiopian Pharmaceutical Supply Agency (EPSA) and are distributed to cancer treatment centers. A free-market purchasing option also exists, but for chemotherapy obtained outside of government-subsidized channels, the potential for substandard or falsified chemotherapy was a concern. Participants expressed confidence that the correct treatment was administered to patients, but viewpoints on reliability and consistency of medication supply were variable. Quantitative data from the survey showed that participants were not confident that medications are prepared safely and correctly. Improper storage and manipulation of high-risk medications remain a significant risk to staff. CONCLUSIONS This study provides insight from a healthcare staff perspective on how gaps in the chemotherapy supply chain process impact patient care in a low-income country. Inventory management, disruptions in supply chain, and product integrity were perceived as the largest gaps in the current chemotherapy supply chain structure.
Collapse
Affiliation(s)
- Kurtis J Stocker
- Department of Pharmacy, University of North Carolina Medical Center, Chapel Hill, NC, USA
| | - Andrew Tiemann
- Department of Pharmacy, University of North Carolina Medical Center, Chapel Hill, NC, USA
| | - Kelly M Brunk
- Department of Pharmacy, University of North Carolina Medical Center, Chapel Hill, NC, USA
| | - Bemnat Agegnehu
- Department of Pharmacy, University of North Carolina Medical Center, Chapel Hill, NC, USA
| | - Kaitlyn Buhlinger
- Department of Pharmacy, University of North Carolina Medical Center, Chapel Hill, NC, USA
| | - Lindsey Amerine
- Department of Pharmacy, University of North Carolina Medical Center, Chapel Hill, NC, USA
- University of North Carolina Eshelman School of Pharmacy, Chapel Hill, NC, USA
| | - Megan C Roberts
- University of North Carolina Eshelman School of Pharmacy, Chapel Hill, NC, USA
- University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA
| | | | - Stephen M Clark
- Department of Pharmacy, University of North Carolina Medical Center, Chapel Hill, NC, USA
- University of North Carolina Eshelman School of Pharmacy, Chapel Hill, NC, USA
| | - Robert Rose
- Department of pharmacy, University of Kentucky HealthCare, Lexington, KY, USA
| | | | | | - Atalay Mulu Fentie
- Addis Ababa University, College of Health Sciences, School of Pharmacy, Addis Ababa, Ethiopia
- Addis Ababa University, College of Health Sciences, Tikur Anbesa Specialized Hospital, Oncology Unit, Addis Ababa, Ethiopia
| | - Thomas B Alexander
- University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA
- University of North Carolina School of Medicine, Chapel Hill, NC, USA
| | - Sachiko Ozawa
- University of North Carolina Eshelman School of Pharmacy, Chapel Hill, NC, USA
| | - Michael Chargualaf
- Department of Pharmacy, University of North Carolina Medical Center, Chapel Hill, NC, USA
| | - Benyam Muluneh
- University of North Carolina Eshelman School of Pharmacy, Chapel Hill, NC, USA
- University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA
| |
Collapse
|
2
|
Palmer S, Patel A, Wang C, Patel B, Zeidner J, Foster M, Muluneh B, Buhlinger K. Outpatient initiation of venetoclax in patients with acute myeloid leukemia. J Oncol Pharm Pract 2023; 29:1590-1598. [PMID: 36474407 DOI: 10.1177/10781552221142872] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2023]
Abstract
INTRODUCTION Venetoclax is a treatment option in patients with acute myeloid leukemia (AML) in both the front-line and relapsed/refractory settings. Initiation of therapy has been previously restricted to the inpatient setting at some institutions due to a risk of tumor lysis syndrome (TLS) and limitations in medication access efficiency given the high cost of therapy. METHODS We assessed the safety of initiating venetoclax in the outpatient setting through a single-arm, retrospective study of adult AML patients between April 1, 2019 and June 30, 2020. RESULTS Eighty-two patients started venetoclax during this time, with 47 (57%) patients initiated in the outpatient setting. Fifty-five percent of patients received venetoclax as first-line treatment for AML (n = 45) and 45% of patients received venetoclax for relapsed/refractory AML (n = 37). Successful initiation, defined as no hospitalizations secondary to TLS within seven days of therapy initiation, occurred in 98% of patients. The rate of TLS was 2.1% (n = 1) following venetoclax initiation. TLS symptoms were managed during hospitalization, requiring only one day of missed AML therapy. Median turnaround time for medication access was three days. Hospitalizations within seven days occurred in 17% of patients (n = 8), with the majority due to febrile neutropenia. CONCLUSIONS The results of our study provide further evidence for the safety and feasibility of initiating venetoclax in the outpatient setting with a pharmacist-led interdisciplinary protocol.
Collapse
Affiliation(s)
- Shannon Palmer
- Department of Pharmacy, Oregon Health and Sciences University Hospital, Portland, OR, USA
| | - Anand Patel
- Department of Pharmacy, Henry Ford Health, Detroit, MI, USA
| | - Christopher Wang
- Department of Pharmacy, MD Anderson Cancer Center, Houston, TX, USA
| | - Bianka Patel
- Department of Medicine for Foster and Zeidner, Department of Pharmacy for Buhlinger and Patel and Muluneh, University of North Carolina Medical Center, Chapel Hill, NC, USA
| | - Joshua Zeidner
- Department of Medicine for Foster and Zeidner, Department of Pharmacy for Buhlinger and Patel and Muluneh, University of North Carolina Medical Center, Chapel Hill, NC, USA
- Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA
| | - Matthew Foster
- Department of Medicine for Foster and Zeidner, Department of Pharmacy for Buhlinger and Patel and Muluneh, University of North Carolina Medical Center, Chapel Hill, NC, USA
- Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA
| | - Benyam Muluneh
- Department of Medicine for Foster and Zeidner, Department of Pharmacy for Buhlinger and Patel and Muluneh, University of North Carolina Medical Center, Chapel Hill, NC, USA
- Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA
- Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA
| | - Kaitlyn Buhlinger
- Department of Medicine for Foster and Zeidner, Department of Pharmacy for Buhlinger and Patel and Muluneh, University of North Carolina Medical Center, Chapel Hill, NC, USA
- Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA
| |
Collapse
|
3
|
Cozad M, Stump SE, Buhlinger K, Collins J, Muir M, Coombs CC, Muluneh B. Evaluation of an interdisciplinary venetoclax initiation process in minimizing risk of tumor lysis syndrome. Leuk Lymphoma 2022; 63:1831-1838. [DOI: 10.1080/10428194.2022.2047963] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
- Monica Cozad
- University of North Carolina Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA
| | - Sarah E. Stump
- Department of Pharmacy, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Kaitlyn Buhlinger
- Department of Pharmacy, University of North Carolina Medical Center, Chapel Hill, NC, USA
| | - James Collins
- University of North Carolina Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA
| | - Michele Muir
- University of North Carolina Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA
| | - Catherine C. Coombs
- Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
| | - Benyam Muluneh
- University of North Carolina Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA
| |
Collapse
|
4
|
Chen Y, Buhlinger K, Perissinotti AJ, Schepers AJ, Benitez L, Auten J, Chen SL, Bixby DL, Burke PW, Pettit KM, Marini BL. Solving coagulation conundrums: comparing prophylaxis strategies in adult patients receiving PEG-asparaginase. Leuk Lymphoma 2022; 63:2663-2670. [DOI: 10.1080/10428194.2022.2087066] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Affiliation(s)
- YeeAnn Chen
- Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Michigan Medicine, Ann Arbor, MI, USA
| | - Kaitlyn Buhlinger
- Department of Pharmacy, University of North Carolina Medical Center, Chapel Hill, NC, USA
| | - Anthony J. Perissinotti
- Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Michigan Medicine, Ann Arbor, MI, USA
| | - Allison J. Schepers
- Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Michigan Medicine, Ann Arbor, MI, USA
| | - Lydia Benitez
- Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Michigan Medicine, Ann Arbor, MI, USA
| | - Jessica Auten
- Department of Pharmacy, University of North Carolina Medical Center, Chapel Hill, NC, USA
| | - Sheh-Li Chen
- Department of Pharmacy, University of North Carolina Medical Center, Chapel Hill, NC, USA
| | - Dale L. Bixby
- Division of Hematology/Oncology, Adult BMT and Leukemia Programs, Department of Internal Medicine, University of Michigan Medical School, Michigan Medicine, Ann Arbor, MI, USA
| | - Patrick W. Burke
- Division of Hematology/Oncology, Adult BMT and Leukemia Programs, Department of Internal Medicine, University of Michigan Medical School, Michigan Medicine, Ann Arbor, MI, USA
| | - Kristen M. Pettit
- Division of Hematology/Oncology, Adult BMT and Leukemia Programs, Department of Internal Medicine, University of Michigan Medical School, Michigan Medicine, Ann Arbor, MI, USA
| | - Bernard L. Marini
- Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Michigan Medicine, Ann Arbor, MI, USA
| |
Collapse
|
5
|
Bryant AL, Buhlinger K. Role of the Advanced Practitioner in the Management of Oral Chemotherapy for Adults With AML. J Adv Pract Oncol 2022; 13:333-336. [PMID: 35663185 PMCID: PMC9126336 DOI: 10.6004/jadpro.2022.13.3.31] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
Recent advances have resulted in an expansion of treatment options for AML, especially targeted therapies and low-intensity regimens. At JADPRO Live Virtual 2021, presenters reviewed novel and targeted oral chemotherapy for adults with AML and discussed multidisciplinary collaboration for patients with complex AML chemotherapy regimens.
Collapse
Affiliation(s)
- Ashley Leak Bryant
- UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, North Carolina
| | - Kaitlyn Buhlinger
- University of North Carolina Medical Center and University of North Carolina Eshelman School of Pharmacy, Chapel Hill, North Carolina
| |
Collapse
|
6
|
Levy S, Fentie AM, Buhlinger K, Clark SM, Korones DN, Miller V, Alexander TB, Weitzman S, Bekele W, Broas J, Shad A, Roberts M, Chargualaf M, Fufa D, Hailu T, Yimer MA, Mustefa M, Gidey AMS, Dinkiye AM, Adam H, Hailu D, Muluneh B. Ethiopian paediatric oncology registry progress report: documentation practice improvements at tertiary care centre in Addis Ababa, Ethiopia. Arch Dis Child 2021; 106:1244-1245. [PMID: 34140309 PMCID: PMC8796695 DOI: 10.1136/archdischild-2021-322485] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 05/24/2021] [Indexed: 11/03/2022]
Affiliation(s)
- Scott Levy
- School of Medicine and Dentristry, University of Rochester Medical Center, Rochester, New York, USA
| | - Atalay Mulu Fentie
- Tikur Anbessa Specialized Hospital, Addis Ababa University, Addis Ababa, Oromia, Ethiopia
| | - Kaitlyn Buhlinger
- University of North Carolina Medical Center, University of North Carolina, Chapel Hill, North Carolina, USA
| | - Stephen M Clark
- University of North Carolina Medical Center, University of North Carolina, Chapel Hill, North Carolina, USA
| | - David N Korones
- The Aslan Project, Washington, DC, USA,Department of Pediatrics, University of Rochester Medicial Center, Rochester, New York, USA
| | - Vanessa Miller
- Lineberger Comprehensive Cancer Center, University of North Carolina System, Chapel Hill, North Carolina, USA
| | - Thomas B Alexander
- University of North Carolina Medical Center, University of North Carolina, Chapel Hill, North Carolina, USA,Lineberger Comprehensive Cancer Center, University of North Carolina System, Chapel Hill, North Carolina, USA
| | - Sheila Weitzman
- Pediatric Hematology/Oncology, Hospital for Sick Children, Toronto, Ontario, Canada
| | | | | | - Aziza Shad
- The Aslan Project, Washington, DC, USA,The Herman & Walter Samuelson Children’s Hospital at Sinai, Sinai Health System, Baltimore, Maryland, USA
| | - Megan Roberts
- University of North Carolina Eshelman School of Pharmacy, University of North Carolina System, Chapel Hill, North Carolina, USA
| | - Michael Chargualaf
- University of North Carolina Medical Center, University of North Carolina, Chapel Hill, North Carolina, USA
| | - Diriba Fufa
- Jimma Medical Center, Jimma University, Jimma, Ethiopia
| | - Tadele Hailu
- St Paul’s Hospital Millennium Medical College, Addis Ababa, Oromia, Ethiopia
| | | | - Mohammed Mustefa
- Ayder Comprehensive Specialized Hospital, Mekelle University, Mekelle, Tigray, Ethiopia
| | | | - Ali Mamude Dinkiye
- Tikur Anbessa Specialized Hospital, Addis Ababa University, Addis Ababa, Oromia, Ethiopia
| | - Haileyesus Adam
- Tikur Anbessa Specialized Hospital, Addis Ababa University, Addis Ababa, Oromia, Ethiopia
| | - Daniel Hailu
- Tikur Anbessa Specialized Hospital, Addis Ababa University, Addis Ababa, Oromia, Ethiopia
| | - Benyam Muluneh
- University of North Carolina Eshelman School of Pharmacy, University of North Carolina System, Chapel Hill, North Carolina, USA
| |
Collapse
|
7
|
Ramkissoon LA, Buhlinger K, Nichols A, Coombs CC, Foster MC, Galeotti J, Kaiser-Rogers K, Richardson DR, Montgomery ND, Zeidner JF. Clonal evolution of Philadelphia chromosome in acute myeloid leukemia after enasidenib treatment. Leuk Lymphoma 2021; 62:3035-3038. [PMID: 34151687 DOI: 10.1080/10428194.2021.1941928] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Affiliation(s)
- Lori A Ramkissoon
- Department of Pathology & Laboratory Medicine, The University of North Carolina School of Medicine, Chapel Hill, NC, USA
| | - Kaitlyn Buhlinger
- Lineberger Comprehensive Cancer Center, The University of North Carolina School of Medicine, Chapel Hill, NC, USA
| | - Angela Nichols
- Lineberger Comprehensive Cancer Center, The University of North Carolina School of Medicine, Chapel Hill, NC, USA
| | - Catherine C Coombs
- Lineberger Comprehensive Cancer Center, The University of North Carolina School of Medicine, Chapel Hill, NC, USA.,Division of Hematology, Department of Medicine, The University of North Carolina School of Medicine, Chapel Hill, NC, USA
| | - Matthew C Foster
- Lineberger Comprehensive Cancer Center, The University of North Carolina School of Medicine, Chapel Hill, NC, USA.,Division of Hematology, Department of Medicine, The University of North Carolina School of Medicine, Chapel Hill, NC, USA
| | - Jonathan Galeotti
- Department of Pathology & Laboratory Medicine, The University of North Carolina School of Medicine, Chapel Hill, NC, USA
| | - Kathleen Kaiser-Rogers
- Department of Pathology & Laboratory Medicine, The University of North Carolina School of Medicine, Chapel Hill, NC, USA.,Department of Pediatrics, The University of North Carolina School of Medicine, Chapel Hill, NC, USA
| | - Daniel R Richardson
- Lineberger Comprehensive Cancer Center, The University of North Carolina School of Medicine, Chapel Hill, NC, USA.,Division of Hematology, Department of Medicine, The University of North Carolina School of Medicine, Chapel Hill, NC, USA
| | - Nathan D Montgomery
- Department of Pathology & Laboratory Medicine, The University of North Carolina School of Medicine, Chapel Hill, NC, USA.,Lineberger Comprehensive Cancer Center, The University of North Carolina School of Medicine, Chapel Hill, NC, USA
| | - Joshua F Zeidner
- Lineberger Comprehensive Cancer Center, The University of North Carolina School of Medicine, Chapel Hill, NC, USA.,Division of Hematology, Department of Medicine, The University of North Carolina School of Medicine, Chapel Hill, NC, USA
| |
Collapse
|
8
|
Muluneh B, Buhlinger K, Deal AM, Zeidner JF, Foster MC, Jamieson KJ, Bates J, Van Deventer HW. A Comparison of Clofarabine-based (GCLAC) and Cladribine-based (CLAG) Salvage Chemotherapy for Relapsed/Refractory AML. Clin Lymphoma Myeloma Leuk 2017; 18:e13-e18. [PMID: 29100976 DOI: 10.1016/j.clml.2017.09.016] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Received: 07/25/2017] [Revised: 09/05/2017] [Accepted: 09/15/2017] [Indexed: 11/24/2022]
Abstract
BACKGROUND Salvage regimens for patients with relapsed/refractory acute myeloid leukemia (rrAML) lack comparative data for superiority. Thus, we conducted a retrospective analysis of clofarabine-based (GCLAC; granulocyte colony-stimulating factor [filgrastim], clofarabine, high-dose cytarabine) versus cladribine-based (CLAG; cladribine, cytarabine, granulocyte colony-stimulating factor [filgrastim]) regimens in rrAML. PATIENTS AND METHODS We identified 41 consecutive patients with rrAML who had received either GCLAC or CLAG from 2011 to 2014. The primary outcome measure was the complete remission (CR) rate defined according to the International Working Group criteria. The secondary outcomes included the proportion of patients who underwent allogenic stem cell transplantation and the rate of relapse-free survival and overall survival. RESULTS We found no significant differences in the baseline characteristics of the patients treated with GCLAC (n = 22) or CLAG (n = 19). The outcomes with these 2 regimens were not significantly different. Patients treated with GCLAC had a CR/CR with incomplete blood count recovery rate of 64% compared with 47% for the patients treated with CLAG (P = .36). Of the GCLAC patients, 45% underwent allogeneic stem cell transplantation compared with 26% of the CLAG patients (P = .32). The median relapse-free survival after GCLAC and CLAG was 1.59 years and 1.03 years, respectively (P = .75). The median overall survival after GCLAG and CLAG was 1.03 years and 0.70 years, respectively (P = .08). The drug costs were significantly different for GCLAC versus CLAG. Using an average wholesale price, the cost per patient per cycle was $60,821.60 for GCLAC and $4910.60 for CLAG. CONCLUSION A single-institutional retrospective analysis found no significant differences in the outcomes between GCLAC and CLAG for rrAML patients, although formal comparisons should be performed in a randomized clinical trial. The cost of GCLAC was greater than that of CLAG, which should be considered when evaluating the choice for the salvage chemotherapy options.
Collapse
Affiliation(s)
- Benyam Muluneh
- Department of Pharmacy, University of North Carolina Medical Center, Chapel Hill, NC; University of North Carolina Eshelman School of Pharmacy, Chapel Hill, NC.
| | - Kaitlyn Buhlinger
- Department of Pharmacy, University of North Carolina Medical Center, Chapel Hill, NC
| | - Allison M Deal
- Biostatistics and Clinical Data Management Core, University of North Carolina, Chapel Hill, NC
| | - Joshua F Zeidner
- Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC; Department of Medicine, University of North Carolina, Chapel Hill, NC
| | - Matthew C Foster
- Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC; Department of Medicine, University of North Carolina, Chapel Hill, NC
| | - Katarzyna Joanna Jamieson
- Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC; Department of Medicine, University of North Carolina, Chapel Hill, NC
| | - Jill Bates
- Department of Pharmacy, University of North Carolina Medical Center, Chapel Hill, NC
| | | |
Collapse
|